Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Crestor delay

Executive Summary

AstraZeneca expects an "approvable" letter for cholesterol agent Crestor (rosuvastatin) at the end of June, consistent with a 12-month user fee deadline, rather than original 10-month expectation. FDA is seeking data and analyses "to support the use of Crestor at higher doses," company says. The 80 mg dose was associated with rhabdomyolysis in Phase III trials (1"The Pink Sheet" Feb. 4, p. 25). The launch will be delayed beyond the third quarter...

You may also be interested in...

AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests

AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts